RxDoctor Payments Data

Daniela Renkiewicz, MD

Internal Medicine · Battle Creek, MINPI 1790783793

Payments from drug & device makers

$9,019in general payments, 2019–2025

Across 545 payments — averaging $16.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • Xeris Pharmaceuticals, Inc.$765
  • Amgen$719
  • Pfizer$658
  • AbbVie$651
  • Amarin Pharma, Inc.$512
  • plus $4K from 40 others

What the payments were for

  • Food & beverage$8,95899%
  • Education$611%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,019 in reported general payments places this provider in the 90th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$71,541
Medicare patients
346
Services billed
756

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin54$73,316
RybelsusSemaglutide34$59,159
EliquisApixaban41$39,157
MounjaroTirzepatide33$38,434
OzempicSemaglutide19$29,494
MyrbetriqMirabegron15$20,080
FarxigaDapagliflozin Propanediol18$18,661
XareltoRivaroxaban13$18,561
JanuviaSitagliptin Phosphate15$15,671
TrulicityDulaglutide12$11,148
Atorvastatin Calcium627$10,777
Levothyroxine Sodium376$5,080
Ibandronate Sodium99$4,678
Losartan Potassium240$4,034
Rosuvastatin Calcium179$3,899

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic$1,464$88,65353 claims
Boehringer IngelheimJardiance$271$73,31654 claims
Lilly USA, LLCMounjaro, Trulicity$336$49,58245 claims
PfizerEliquis$658$39,15741 claims
Astellas Pharma US IncMyrbetriq$133$20,08015 claims
AstraZenecaFarxiga$485$18,66118 claims
Johnson & JohnsonXarelto$434$18,56113 claims
MerckJanuvia$351$15,67115 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$18$5,080376 claims
AbbVieSynthroid$651$2,36338 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Battle Creek

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →